TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM)

Clinical trials for TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM) explained in plain language.

Never miss a new study

Get alerted when new TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM) trials appear

Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Heart Drug's nerve protection put to the test in real patients

Disease control Completed

This study looked back at existing medical records to see if a high dose of the drug tafamidis (Vyndamax) could slow down nerve damage in people with a specific type of heart disease called mixed-phenotype ATTR-CM. It involved 50 adults who had already been taking the drug for at…

Matched conditions: TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM)

Sponsor: Pfizer • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM)

Get alerted when new TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM) trials appear

Heart Drug's nerve protection put to the test in real patients